Board of Directors

Chairman of the Board since 2011

Björn has more than 25 years of experience in international marketing, sales and business development in pharmaceuticals, medical equipment, and biotechnology, including in Novo Nordisk, AstraZeneca and Medtronic. Recently he has held positions as business development and investment manager at GU Ventures and Global Marketing and Communications Director at ABIGO Medical AB. Björn is currently CEO of Observe Medical, a medtech company listed on Oslo stock exchange

Number of shares and warrants:
11 115 shares
Warrants granting acquisition rights to:
10 833 shares (2020/2023, incentive program)
5 557 shares (TO2 2020/2022)

Education: MSc in Mechanical Engineering at Chalmers University

Other assignments: Vice Chairman of the Board of IML, the trade association of Swedish Innovative small and Middle-sized Life science companies

Independent in relation to both the company and its management as well as to major shareholders.

Board member since 2021

Anders has more than 25 years of experience within international finance and business development in the pharmaceutical– and medical device industries. His experience includes Business- and Corporate Development from Pharmacia & Upjohn, Q-Med AB (publ), partner and CEO at venture  capital firm Nexttobe AB and Executive VP and CFO at Oasmia Pharmaceutical AB (publ). In addition, Anders has extensive board experience from pharma- and tech sectors including, but not limited to, Hansa Biopharma AB (publ), Biolamina AB, Delta Projects AB,  Selego AB. 

Number of shares and warrants: – 

Education: BSc in Business Administration and Economics at Uppsala University  

Ongoing assignments: Chairman of the board of Maida Vale Capital AB, board member of Hunterhex International Inc, Hunterhex AB,      Wonderboo AB, Rosland Nordic AB and Challengehop Inc.  

Independent in relation to the company and its management but not to major shareholders. 

Board member since 2020

Per-Göran has 35 years of experience from the pharmaceutical industry. He has extensive experience in pharmacology and neuropharmacology from Kabi, Kabi Pharmacia, Pharmacia & Upjohn and Pharmacia, AstraZeneca and Albireo. Per-Göran is the founder of Albireo AB and currently VP Development for Albireo Pharma Inc and its subsidiary Albireo AB and is affiliated with the Division of Translational Alzheimer Neurobiology, Karolinska Institute, Stockholm.

Number of shares and warrants:
4 000 shares
Warrants granting acquisition rights to:
10 833 shares (2020/2023, incentive program)
2 000 shares (TO2 2020/2022)

Education: MSc in Chemistry, PhD in Medical Science, Adjunct Professor of Neuroscience at Uppsala University

Ongoing assignments: Co-opted to the Center for Alzheimer Research at Karolinska Institute

Independent in relation to both the company and its management as well as to major shareholders.

Board member since 2015

Clas is a physician at the Neurology clinic and at the laboratory for clinical immunology at Sahlgrenska University Hospital in Gothenburg. Since 2001 he has conducted research within Multiple Sclerosis (MS) at the hospital’s Multiple sclerosis centre and the Department of Clinical Neuroscience, University of Gothenburg. In addition to academic research, he has participated in several clinical drug trials in MS led by Biogen-Idec, Merck, Novartis, Roche and Sanofi, several of which resulted in today’s standard treatments for MS.

Number of shares and warrants:
8 000 shares
Warrants granting acquisition rights to:
10 000 shares (2020/2023, incentive program)
4 500 shares (TO2 2020/2022)

Education: MD and PhD in Medicine, Senior consultant in Neurology and Clinical Immunology

Other assignments: –

Independent in relation to both the company and its management as well as to major shareholders.

Board member since 2018

Carol is an R&D and pharmaceutical development expert with more than 30 years of experience in UK and US-based pharmaceutical and biotechnology companies focusing on drug acquisition and profiling of NCE biology. She has played a key role in GSK Biopharmaceuticals, including management in pharmaceutical research and development activities in several therapeutic areas, especially in the areas of immuno-inflammatory diseases and neuroscience with an emphasis on translational medicine. She recently managed a semi-philanthropic dementia fund with a central focus on identifying and developing new disease-modified mechanisms for the treatment of all different types of dementia. She has over 90 articles published in scientific journals. Until recently Carol was the Director of Research and Managing Director of EDoN, a global early detection initiative at Alzheimer’s Research UK. She has since taken on the role of Chief Medical and Scientific Officer at Small Pharma, a biotech developing treatments for mental health disorders.

Number of shares and warrants:
Warrants granting acquisition rights to:
10 833 shares (2020/2023, incentive program)

Education: BSc, PhD in Neuro Pharmacology

Ongoing assignments: –

Independent in relation to both the company and its management as well as to major shareholders.

Board member since 2020

Pernilla has 30 years of experience from the pharmaceutical and biotech industry. She has worked with clinical research activities as project manager and manager as well as with strategic work in clinical research at Merck & Co. Inc. (MSD). Pernilla is currently Chief Operating Officer at InDex Pharmaceuticals Holding AB (publ)

Number of shares and warrants:
Warrants granting acquisition rights to:
10 833 shares (2020/2023, incentive program)

Education: MSc in Pharmacy

Ongoing assignments: Board member of InDex Pharmaceuticals AB, InDex Diagnostics AB and IML, the trade association of Swedish Innovative small and Middle-sized Life science companies.

Independent in relation to both the company and its management as well as to major shareholders.

Board member since 2018

Anders has held several senior roles in Astra, AstraZeneca, CV Therapeutics, Actogenics and Tikomed AB. He has previous experience in management, business development and pharmaceutical development.

Number of shares and warrants: –

Education: Trained dentist (DDS)

Ongoing assignments: Chairman of the board Transmed Gothenburg AB, Sobrera Pharma AB, Sortina Pharma AB and Iscaff Pharma AB. Board member of Anders Waas AB, Gudna Pharma AB, Ectin research AB and Toleranzia AB.

Independent in relation to both the company and its management and dependent of major shareholders.

Board member since 2020

Lena has 20 years of experience from the pharmaceutical industry. She has extensive experience in regulatory affairs and development of biological drugs and vaccines from Dilafor, Avaris AB, Independent Pharmaceutica AB, SBL Vaccines, Accuro Immunology and the Swedish Medical Products Agency. Lena is currently CEO of Dilafor AB.

Number of shares and warrants:
Warrants granting acquisition rights to:
10 833 shares (2020/2023, incentive program)

Education: MSc in Pharmacy, PhD in pharmaceutical science

Ongoing assignments: Chairman of the board in Simplexia AB, CellProtect Nordic Pharmaceuticals AB and Dilafor Incentive AB

Independent in relation to both the company and its management as well as to major shareholders.